Addressing Antibiotic Resistance: A Global Threat
This presentation includes certain forward-looking statements that are based upon current expectations of management, which involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “anticipate”, “become”, “believe”, “can”, “estimate”, “prospective”, “further”, “targeting”, “would” and similar expressions.

Statements about uses of the technologies described in this presentation, including their importance to animal or human health, their novelty, safety, efficacy or affordability, whether Avivagen’s technology will continue to generate the positive results achieved in previous trials, whether trials conducted by third parties will achieve different results from those achieved by Avivagen; whether Avivagen’s technology can be extended into human health applications, deaths attributable to anti-microbial resistance in the future, the ability of producers to obtain a return on their investment in Avivagen’s products, the anticipated value of Avivagen’s products for potential commercialization / distribution partners, whether the product has utility across multiple species, whether our sole source manufacturer can continue to supply Avivagen’s product, proposed future activities including development and growth of commercial partnerships, future allocation of Avivagen’s resources, the proposed relaunch of companion animal products and related studies, whether the provisional patent filed by Avivagen will result in the granting of a patent and anticipated future trials are all forward looking statements.

These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Such Avivagen risks and uncertainties include, but are not limited to, the following: the accuracy of third party information included in this presentation; Avivagen’s ability to continue as a going concern; the results of ongoing or future trials may not be positive or sufficiently positive; even if the results of trials are positive, there is no guarantee that its products will be commercially successful or that requisite regulatory approvals will be obtained; the timing and results of trials may be delayed or may not be completed at all; and intellectual property rights may prove inadequate to protect its inventions.

Accordingly, you should not place undue reliance on forward-looking statements. Please refer to the risk factors relating to Avivagen’s business as outlined in its Management’s Discussion and Analysis of Financial Condition and Results of Operations for the year ended October 31, 2016 and other securities filings available at www.SEDAR.com.

Except as required by law, Avivagen Inc. assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.

THIS DOCUMENT DOES NOT CONSTITUTE AN OFFER TO SELL, AN INVITATION TO INDUCE AN OFFER, OR A SOLICITATION OF AN OFFER TO ACQUIRE, THE SHARES OF THE CORPORATION IN ANY JURISDICTION.
**ANTIBIOTICS**

- Antibiotics are among the most powerful scientific discoveries ever made

Sir Alexander Fleming Discovered Penicillin in 1928

- Antibiotics save millions of lives every year

- However, antibiotics are becoming ineffective with the *rise of antibiotic or antimicrobial resistance*
In the U.S. alone, the CDC says that resistant bacteria cause:

- At least 2 million infections per year
- 23,000 deaths per year
- Costs of $20 billion per year
- and 8 million hospital days

More resistant bacteria infections per year than cancer diagnoses

It is a global, real and growing problem
At UN, global leaders commit to act on antimicrobial resistance

Collective effort to address a challenge to health, food security, and development

21 September 2016, New York — World leaders today signaled an unprecedented level of attention to curb the spread of infections that are resistant to antimicrobial medicines.

Antimicrobial resistance (AMR) happens when bacteria, viruses, parasites, and fungi develop resistance against medicines that were previously able to cure them.

For the first time, Heads of State committed to taking a broad, coordinated approach to address the root causes of AMR across multiple sectors, especially human health, animal health and agriculture. This is only the fourth time a health issue has been taken up by the UN General Assembly (the others were HIV, noncommunicable diseases, and Ebola). The high-level meeting was convened by the President of the 71st session of the UN General Assembly, H.E. Peter Thomson.

“Antimicrobial resistance threatens the achievement of the Sustainable Development Goals and requires a global response”, Mr. Thomson said. “Member States have today agreed upon a strong Political declaration that provides a good basis for the international community to move forward. No one country, sector or organization can address this issue alone.”
A PROBLEM OF GLOBAL SCALE

Deaths attributable to antimicrobial resistance every year by 2050

- Europe: 390,000
- North America: 317,000
- Latin America: 392,000
- Africa: 4,150,000
- Asia: 4,730,000
- Oceania: 22,000

Reference source - https://www.weforum.org/agenda
THE WORLD IS WAKING UP TO THIS PROBLEM!
The primary and majority use of antibiotics is in food animals!

- Antibiotic Use Estimates in the U.S.
  - 70% Livestock: Non-Therapeutic
  - 6% Livestock: Therapeutic
  - 15% Other
  - 9% Human: Therapeutic

- Drug Binge
  - China consumes half the world’s antibiotics, with the majority administered to animals

- Pounds of antibiotics sold
  - 2001
  - 2011

- Humans vs. Animals
  - China
  - Humans: 77,760
  - Animals: 84,240
  - 162,000 of antibiotics used in total

We address the problem at the source
PROBLEM:

• **Antibiotic resistance** is an important, global, human health concern, with massive negative economic impacts.
• Many **food producers depend on in-feed antibiotics** to reliably prevent disease and boost growth in livestock.
• Governments are taking action to reduce/ban antibiotics as growth promoters

RESOLUTION:

• Avivagen has a solution: a unique and validated technology enabling discontinuation of the use of antibiotics for growth promotion and disease prevention.
• Does NOT contribute to the development of “superbugs”
We believe we have a First-In-Class technology and product
  • Old technologies and generic products are common
✓ Proven Modes of Action (non-antibiotic)
  • Published in peer-reviewed scientific literature
✓ Consistent Efficacy
  • Supported by results of 16 trials
✓ Economically Advantageous
  • Productivity gains offer producers return on their investment
✓ Excellent Handling Properties
  • Remains active during feed production, stable long-term storage
✓ Utility Across Multiple Species
  • Innate immunity is found in all animal species
✓ Defined Manufacturing Processes
  • Consistent composition and concentration of active
✓ Extensive IP Protection with long life into the late 2020s and mid 2030s
  • High value for potential commercialization/distribution partners
  • Strong barriers to entry
OxC-beta™ LIVESTOCK SELECTED RESULTS

Broiler Poultry – #1 global feed market (295 million tons)

- Daily weight gain improved by up to 12%
- Feed conversion improved by up to 4%
- Significant protection against enteric disease (NE)

Swine – #2 global feed market (254 million tons)

- Daily weight gain improved by up to 13% - 20%
- Feed conversion improved by up to 11%
- Protection from post-wean diarrhea (ETEC)

OxC-beta™ Livestock provides consistent benefits to animal health and producer economics.
• This is a global, multi-billion dollar market opportunity

• **1 Billion tons** of feed sold per year
  • US$300 – US$450 per ton of feed

• OxC-Beta™ Livestock would be added to the feed at attractive economics to Avivagen

• This could represent a multi-billion dollar opportunity to Avivagen per year
COMMERICAL SALES RAMP JUST BEGINNING

• OxC-Beta™ for Livestock is now approved for sale in several countries

• Targeting opening up all major markets as quickly as possible

• Bringing on regulatory experts to do it right

• In discussions with very large companies for distribution agreements

• First commercial sales with a repeat purchase in the Philippines
  • Distribution via UNAHCO, the 2nd largest feed company there

• Avivagen intends to partner with established companies that have the resources and relationships to gain significant market share
<table>
<thead>
<tr>
<th><strong>TICKERS / EXCHANGES</strong></th>
<th><strong>VIV - TSXV, CHEXF - OTC PINK</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>SHARE PRICE (April 28, 2017)</td>
<td>$0.125</td>
</tr>
<tr>
<td>MARKET CAP</td>
<td>$36.25 MILLION</td>
</tr>
<tr>
<td>52 WEEK HI-LOW</td>
<td>$0.215 - $0.06</td>
</tr>
<tr>
<td>SHARES OUTSTANDING (BASIC)</td>
<td>290 MILLION</td>
</tr>
<tr>
<td>AVERAGE DAILY VOLUME (LAST 3 MONTHS)</td>
<td>465,000 SHARES</td>
</tr>
<tr>
<td>SHARE OWNERSHIP</td>
<td>INSIDERS: ~10% PATHFINDER ASSET MANAGEMENT: &gt;10% OTHER INSTITUTIONS: &gt;10% FLOAT: ~70%</td>
</tr>
<tr>
<td>BURN RATE</td>
<td>$350,000/MONTH (EXCLUDES ANY CASH FLOW FROM SALES) (LAST REPORTED CASH:</td>
</tr>
<tr>
<td>LAST REPORTED CASH (JAN 31, 2017)</td>
<td>$5.5 MILLION</td>
</tr>
</tbody>
</table>
UPCOMING MILESTONES

OUR GOALS

• Further trials and results from potential partners
• Gain approvals for additional species (beyond poultry and swine)
• Broader product launch in Asia with ramping, material product sales
• Hire a regulatory consultant to optimize market access
• Engage with U.S., Canadian and European regulators
  • Other jurisdictions also being pursued
• Confirm path and timeline for additional market access
• Sign with a major distributor
• Advance human health initiatives
• Recruit a new CEO
Kym Anthony, Independent Chair & Interim CEO
Capital Markets, Agriculture, Life Sciences
(Past Chairman of ProMetic Life Sci. & IDA)

Jeffrey Kraws, Independent
Life Sciences & Capital Markets
Former Top Ranked Analyst for Pharmaceutical Stocks
(CEO & Co-Founder of Crystal Research)

Vanessa Grant, Independent
Governance & Securities Law, Life Sciences
(Partner at Norton Rose Fulbright Canada LLP)

Paul Mesburis, Independent Audit Committee Chair
Capital Markets & Life Sciences
(Chair of the Audit & Risk Committee of ProMetic Life Sciences)

Graham Burton, Management
Scientific Co-Founder, NRC Chemist

David Hankinson, Management
Former Pharma CEO
(Solvay Pharma Inc.)
RECAP: THE OxC-beta™ LIVESTOCK SOLUTION

ANTIBIOTIC GROWTH PROMOTERS ➔ Getting phased out

- ✔ Consistent benefits to performance
- ✔ Protection from common production environment infections
- ✔ Applicable in multiple food animal species
- ✔ Provides broad spectrum of protection against many different pathogens
- ✗ Does not promote the rise of resistant bacteria
www.avivagen.com

Contact:
Kym Anthony
Chairman and Interim CEO

k.anthony@avivagen.com

THANK YOU